Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346231 | 0.87 | ALDH1A1 (0.61) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL10951363 | 0.87 | ALDH1A1 (0.67) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL8105314 | 0.85 | ALDH1A1 (0.60) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL11022928 | 0.85 | ALDH1A1 (0.65) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL9636234 | 0.83 | ALDH1A1 (0.58) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL27438319 | 0.83 | ALDH1A1 (0.57) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL10721861 | 0.81 | ALDH1A1 (0.55) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL11202055 | 0.80 | ALDH1A1 (0.73) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL2395370 | 0.80 | ALDH1A1 (0.66) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL814874 | 0.79 | ALDH1A1 (0.62) | ALDH1A1MAPTPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1233292-A | — | — | None | — | — | JP | disclosed |
| US-7829580-B2 | Cyclic amine derivative having heteroaryl ring | SANKYO COMPANY, LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| US-20090306059-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| US-7396930-B2 | making spiro(benzo(c)thiophene-1 (3H),4'-piperidine) derivatives; involves reacting a mercapto compound with a 2-halophenylalkyl halide, reacting with an alkyllithium, then N-ethoxycarbonyl-4-piperidone, dehydration and cyclization; industrial scale; novel intermediates to neurokinin receptor antagonist | SANKYO COMPANY, LIMITED (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7365067-B2 | Indanol derivative | SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| EP-1889835-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20070197570-A1 | Indanol derivative | SANKYO COMPANY, LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20060270706-A1 | Cyclic amine derivative having heteroaryl ring | SANKYO COMPANY, LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1695962-A1 | CYCLIC AMINE DERIVATIVE HAVING HETEROARYL RING | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-7012147-B2 | Enzyme inhibitors; chemical intermediates | SANKYO COMPANY, LIMITED (JP) | 2006-03-14 | — | — | US | disclosed |
| US-6159967-A | Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use | SANKYO COMPANY, LIMITED (JP) | 2000-12-12 | — | — | US | disclosed |
| EP-1048658-A1 | ALICYCLIC ACYLATED HETEROCYCLIC DERIVATIVES | Sankyo Company Limited (JP) | 2000-11-02 | — | — | EP | disclosed |
| US-6013663-A | CATARACT THERAPY OR PREVENTION | SANKYO COMPANY, LIMITED (JP) | 2000-01-11 | — | — | US | disclosed |
| US-5928851-A | Photographic couplers which release useful groups anchiomerically and their synthesis | EASTMAN KODAK COMPANY (US) | 1999-07-27 | — | — | US | disclosed |
| US-5925664-A | VISION DEFECTS | SANKYO COMPANY, LIMITED (JP) | 1999-07-20 | — | — | US | disclosed |
| EP-0814376-A2 | Photographic couplers which release useful groups anchiomerically and their synthesis | EASTMAN KODAK COMPANY (US) | 1997-12-29 | — | — | EP | disclosed |
| EP-0795326-A1 | OCULAR TENSION DEPRESSANT | SANKYO COMPANY LIMITED (JP) | 1997-09-17 | — | — | EP | disclosed |
| EP-0708769-A1 | SUBSTITUTED 2-FUSED PHENYLPYRIDINES WITH HERBICIDAL ACTIVITY | BASF AKTIENGESELLSCHAFT (DE) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002590-A2 | SUBSTITUTED 2-FUSED PHENYLPYRIDINES WITH HERBICIDAL ACTIVITIES | BASF AKTIENGESELLSCHAFT (DE) | 1995-01-26 | — | — | WO | disclosed |
| JP-H01233292-A | METHOD FOR GLYCOSYLATION | OGURA HARUO | 1989-09-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270706-A1 | Cyclic amine derivative having heteroaryl ring | F12, F2, H1-3 | ALDH1A1 1073/4885MAPT 4841/4885POLB 3995/4885 |
| US-20070197570-A1 | Indanol derivative | BDKRB2, BDKRB1, TACR2 | ALDH1A1 1329/4885MAPT 3872/4885POLB 3820/4885 |
| US-20090306059-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | CBR3, CNR1, C3AR1 | ALDH1A1 2601/4885MAPT 4874/4885POLB 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.